American Board of Radiology
Cancer, Computed Tomography, Hepatitis C Virus, Liver, MRI, Magnetic Resonance Imaging, Transplantation
MD, Emory University School of Medicine
MD, University of Missouri Kansas City Sch of Medicine
Internship, Internal Medicine
Massachusetts General Hospital
Fellowship, MRI/CT/Body Img.
New York University School of Medicine
Lewis S, Vasudevan P, Chatterji M, Besa C, Jajamovich G, Facciuto M, Taouli B. Comparison of gadoxetic acid to gadobenate dimeglumine for assessment of biliary anatomy of potential liver donors. Abdominal radiology (New York) 2016 Mar;.
Lewis S, Kamath A, Chatterji M, Patel A, Shyknevsky I, Dyvorne HA, Kuehn B, Taouli B. Diffusion-weighted imaging of the liver in patients with chronic liver disease: comparison of monopolar and bipolar diffusion gradients for image quality and lesion detection. AJR. American journal of roentgenology 2015 Jan; 204(1).
Aronhime S, Calcagno C, Jajamovich GH, Dyvorne HA, Robson P, Dieterich D, Fiel MI, Martel-Laferriere V, Chatterji M, Rusinek H, Taouli B. DCE-MRI of the liver: effect of linear and nonlinear conversions on hepatic perfusion quantification and reproducibility. Journal of magnetic resonance imaging : JMRI 2014 Jul; 40(1).
Lim RP, Fan Z, Chatterji M, Baadh A, Atanasova IP, Storey P, Kim DC, Kim S, Hodnett PA, Ahmad A, Stoffel DR, Babb JS, Adelman MA, Xu J, Li D, Lee VS. Comparison of nonenhanced MR angiographic subtraction techniques for infragenual arteries at 1.5 T: a preliminary study. Radiology 2013 Apr; 267(1).
Lee SI, Krishnaraj A, Chatterji M, Dreyer KJ, Thrall JH, Hahn PF. When does a radiologist's recommendation for follow-up result in high-cost imaging?. Radiology 2012 Feb; 262(2).
Chatterji M, Mercado CL, Moy L. Optimizing 1.5-Tesla and 3-Tesla dynamic contrast-enhanced magnetic resonance imaging of the breasts. Magnetic resonance imaging clinics of North America 2010 May; 18(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Chatterji did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.